NIKKEI 225
27,497.45 +20.58 (+0.07%) HANG SENG
19,682.13 +114.44 (+0.58%) CRUDE OIL
72.75 -0.06 (-0.08%) GOLD FUTURES
1,961.20 +7.40 (+0.38%) DOW
32,432.08 +194.55 (+0.60%) BTC-GBP
21,847.49 -774.23 (-3.42%)
ABIONYX Pharma SA (0RAG.L)
| Previous close | 1.9440 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 48.397M |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1380 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, March 06, 2023--Regulatory News: ABIONYX Pharma (Paris:ABNX):
- Business Wire
ABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the 4th Quarter 2022
TOULOUSE, France & LAKELAND, Mich., February 28, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today provides an update on its activity and cash position as of December 31, 2022.
- Business Wire
ABIONYX Pharma: Press Release
TOULOUSE, France & LAKELAND, Mich., February 03, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today that it has been informed by TVM Capital of the total sale of their shares on the market due to the liquidation of their funds that have reached maturity.
